RAP2C, member of RAS oncogene familyGenealiases: []
Q-omics provides the consensus-scored RAP2C profile across patient tissues and cancer cell-line models. RAP2C expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RAP2C is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RAP2C RNA expression shows 19,436 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where RAP2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP2C survival associations across molecular data types. RAP2C RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP2C RNA expression–survival associations across cancer types. High RAP2C expression shows unfavorable associations in KIRP, KICH, UVM and LGG, but favorable associations in SKCM and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RAP2C RNA expression.
This table summarizes RAP2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAP2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP2C shows higher tumor expression in HNSC, STAD, BRCA, READ, LIHC and BLCA. The HNSC box plot shows higher RAP2C RNA expression in tumor versus normal tissue (log2 FC = +1.436, t-test p < 0.001).
This table shows molecular features associated with RAP2C in patient tissues and cancer cell lines. In patient samples, RAP2C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAP2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
